NCT04792580 - The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 22, 2022

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions

Graft-versus-host-diseaseOcular Graft-versus-host Disease

Interventions

DRUG

Lifitegrast 5% Ophthalmic Solution

Used twice a day in both eyes for 4 weeks after a 2 week washout.

DRUG

Placebo

Used twice a day in both eyes for 4 weeks after a 2 week washout with the same drops.

Trial Locations (1)

Richard W Yee, MD PLLC, Bellaire